Purple Biotech (PPBT) Current Deferred Revenue (2019)

Purple Biotech's (PPBT) quarterly Current Deferred Revenue came in at $961000.0 in Q4 2019.

Purple Biotech (PPBT) Current Deferred Revenue (2019) Analysis & Trends

Purple Biotech (PPBT) has 1 years of Current Deferred Revenue data on file, last reported at $961000.0 in Q4 2019.

On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $961000.0 in Q4 2019; TTM through Dec 2019 was $961000.0, a N/A change from a year earlier, with the FY2019 full-year figure at $961000.0, changed N/A from the prior year.
Current Deferred Revenue for Q4 2019 stood at $961000.0.
Over the last five years, Current Deferred Revenue for PPBT reached as high as $961000.0 in Q4 2019 and fell as low as $961000.0 in Q4 2019.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Purple Biotech	1.33 Bn	1.33 Bn	-

Historic Data

Download Data

Date	Value
Dec 31, 2019	961,000.00